
Antihypertensive Drugs Market Report by Therapeutic Class (Diuretics, ACE Inhibitors, Calcium Channel Blockers, Beta-adrenergic Blockers, Vasodilators, and Others), Type (Primary Hypertension, Secondary Hypertension), Distribution Channel (Retail Pharmacy
Description
Antihypertensive Drugs Market Report by Therapeutic Class (Diuretics, ACE Inhibitors, Calcium Channel Blockers, Beta-adrenergic Blockers, Vasodilators, and Others), Type (Primary Hypertension, Secondary Hypertension), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-Commerce), and Region 2024-2032
The global antihypertensive drugs market size reached US$ 29.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 38.0 Billion by 2032, exhibiting a growth rate (CAGR) of 2.7% during 2024-2032. The increasing prevalence of hypertension, rising number of patients suffering from CVDs, and the growing number of clinical studies represent some of the key factors driving the market.
Antihypertensive drugs are utilized to treat hypertension wherein the force of blood against the walls of the arteries becomes high and can increase the risk of heart disease, stroke, and other health problems. They generally comprise diuretics, beta-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and vasodilators. They work by relaxing the blood vessels, reducing the amount of fluid in the blood vessels, and decreasing the amount of hormones that cause blood vessels to constrict. They also slow down the heartbeat, maintain a healthy systolic BP, improve life expectancy, and minimize the risk of premature death. At present, key players are introducing imidazolines, monatepil, and neutral endopeptidase inhibitors to expand their product portfolio.
Antihypertensive Drugs Market Trends:
The surging prevalence of hypertension and high BP among individuals represents one of the major factors driving the demand for antihypertensive drugs around the world. Moreover, the growing geriatric population that is susceptible to developing these medical disorders is influencing the market positively. In addition, the increasing number of patients suffering from cardiovascular diseases (CVDs) on account of sedentary lifestyles, unhealthy dietary patterns, high-stress levels, diabetes, and obesity among the masses is favoring the growth of the market. Apart from this, governing agencies of numerous countries are initiating campaigns to spread awareness about the hypertension disorder, its symptoms, diagnosis, and treatment. This, coupled with the rising number of clinical studies and trials to develop new treatments for hypertension, is strengthening the growth of the market. Furthermore, the growing usage of over the counter (OTC) drugs to treat BP-related diseases on account of expanding healthcare costs is creating a positive outlook for the market. Besides this, there is a rise in the number of online retail platforms that offer antihypertensive drugs according to the dosage needed by the consumer. This, along with significant growth in the pharmaceutical and e-commerce industries, is propelling the growth of the market. Additionally, the increasing adoption of health insurance policies that provide financial assistance for hypertension treatment and minimize healthcare expenses is impelling the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global antihypertensive drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on therapeutic class, type and distribution channel.
Therapeutic Class Insights:
- Diuretics
- ACE Inhibitors
- Calcium Channel Blockers
- Beta-adrenergic Blockers
- Vasodilators
- Others
Type Insights:
- Primary Hypertension
- Secondary Hypertension
Distribution Channel Insights:
- Retail Pharmacy
- Hospital Pharmacy
- E-Commerce
Regional Insights:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global antihypertensive drugs market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include AstraZeneca, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Johnson & Johnson Services Inc., Lupin Pharmaceuticals Inc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report:
- How has the global antihypertensive drugs market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global antihypertensive drugs market?
- What is the impact of each driver, restraint, and opportunity on the global antihypertensive drugs market?
- What are the key regional markets?
- Which countries represent the most attractive antihypertensive drugs market?
- What is the breakup of the market based on the therapeutic class?
- Which is the most attractive therapeutic class in the antihypertensive drugs market?
- What is the breakup of the market based on the type?
- Which is the most attractive type in the antihypertensive drugs market?
- What is the breakup of the market based on the distribution channel?
- Which is the most attractive distribution channel in the antihypertensive drugs market?
- What is the competitive structure of the global antihypertensive drugs market?
- Who are the key players/companies in the global antihypertensive drugs market?
Table of Contents
143 Pages
- 1 Preface
- 2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
- 5 Global Antihypertensive Drugs Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
- 6 Market Breakup by Therapeutic Class
- 6.1 Diuretics
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 ACE Inhibitors
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Calcium Channel Blockers
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Beta-adrenergic Blockers
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Vasodilators
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Others
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
- 7 Market Breakup by Type
- 7.1 Primary Hypertension
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Secondary Hypertension
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 8 Market Breakup by Distribution Channel
- 8.1 Retail Pharmacy
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Hospital Pharmacy
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 E-Commerce
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
- 10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
- 11 Value Chain Analysis
- 12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
- 13 Price Analysis
- 14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 AstraZeneca
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Boehringer Ingelheim International GmbH
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 Daiichi Sankyo Company Limited
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Johnson & Johnson Services Inc.
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Lupin Pharmaceuticals Inc
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.6 Merck & Co. Inc.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 Novartis AG
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Pfizer Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Sanofi
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Sun Pharmaceutical Industries Ltd.
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.